Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*39 allele family.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
A variant of the GUILLAIN-BARRE SYNDROME characterized by the acute onset of oculomotor dysfunction, ataxia, and loss of deep tendon reflexes with relative sparing of strength in the extremities and trunk. The ataxia is produced by peripheral sensory nerve dysfunction and not by cerebellar injury. Facial weakness and sensory loss may also occur. The process is mediated by autoantibodies directed against a component of myelin found in peripheral nerves. (Adams et al., Principles of Neurology, 6th ed, p1313; Neurology 1987 Sep;37(9):1493-8)
A chronic inflammatory process that affects the AORTA and its primary branches, such as the brachiocephalic artery (BRACHIOCEPHALIC TRUNK) and CAROTID ARTERIES. It results in progressive arterial stenosis, occlusion, and aneurysm formation. The pulse in the arm is hard to detect. Patients with aortitis syndrome often exhibit retinopathy.
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Scandinavia, in a medical context, often refers to a geographical region consisting of Denmark, Norway, and Sweden, where shared cultural, linguistic, and historical ties can influence the delivery, organization, and research of healthcare systems.

The recognition of HLA-B27 by human CD4(+) T lymphocytes. (1/141)

HLA-B27 transgenic animal models suggest a role for CD4(+) T lymphocytes in the pathogenesis of the spondyloarthropathies, and murine studies have raised the possibility that unusual forms of B27 may be involved in disease. We demonstrate that CD4(+) T cells capable of recognizing B27 can be isolated from humans by coculture with the MHC class II-negative cell line T2 transfected with B27. These CD4(+) T cells recognize a panel of B27-transfected cell lines that are defective in Ag-processing pathways, but not the nontransfected parental cell lines, in a CD4-dependent fashion. Inhibition of responses by the MHC class I-specific mAb w6/32 and the B27 binding mAb ME1 implicates the recognition of a form of B27 recognized by both of these Abs. We suggest that B27-reactive CD4(+) T cells may be pathogenic in spondyloarthropathies, particularly if factors such as infection influence expression of abnormal forms of B27.  (+info)

Heat shock protein 70 gene polymorphisms in Mexican patients with spondyloarthropathies. (2/141)

OBJECTIVE: To investigate the role of HSP70 genes as contributors to genetic susceptibility of the spondyloarthropathies (SpA) in the Mexican population. METHODS: The study included 150 patients with SpA (undifferentiated spondyloarthropathy (uSpA) 68, ankylosing spondylitis (AS) 60, and reactive arthritis 22) and 158 healthy controls. HSP70-1, HSP70-2 and HSP70-hom genotypes were analysed by the polymerase chain reaction-restriction fragment length polymorphism technique. Statistical methods included the Mantel-Haenzel, chi(2), Fisher's exact test, and Woolf's method for odds ratio (OR). RESULTS: HSP70-2 B/B genotype frequency was increased in the whole group of patients with SpA (pC<0.05, OR=4.3), as well as in the different clinical subgroups (pC<0.05, OR=4.2 for AS; pC<0.05, OR=4.4 for uSpA; and pC<0.05, OR=4.1 for ReA). This frequency remained significantly increased when the patients with B27 negative SpA were analysed. On the other hand, HSP70-hom locus analysis showed significantly increased frequency of A allele in the whole group of SpA (pC<0.05, OR=3.4), as well as in the groups with AS (pC<0.05, OR=5.6) and with uSpA (pC<0.05, OR=3.1), when compared with healthy controls. In this case, also, the genotype A/A was increased in the whole group of SpA (pC<0.05, OR=4.5), as well as in patients with AS (pC<0.05, OR=6.4) and with uSpA (pC<0.05, OR=3.7). When the patients with B27 negative SpA were analysed the frequencies of HSP70-hom A allele and A/A genotype remained significantly increased in the whole group of SpA (pC<0.05, OR=3.2 for the A allele and pC<0.05, OR=4.2 for the A/A genotype) and in the uSpA subgroup (pC<0.05, OR=3.8 for the A allele and pC<0.05, OR=4.3 for the A/A genotype). CONCLUSION: In addition to the association of SpA with HLA-B27, there is a significant association of HSP70-2 and HSP70-hom alleles with SpA in Mexicans. This association seems to be independent of the susceptibility conferred by HLA-B27 in the group of patients with uSpA.  (+info)

The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families. (3/141)

OBJECTIVES: To investigate whether HLA alleles, other than HLA-B27, influence predisposition to spondyloarthropathy (SpA) in multiplex families. METHODS: Seventy French families with at least two affected SpA members were recruited. Patients, and their first degree relatives were typed for HLA-A, B, C, and DR, and extended HLA haplotypes were determined. The distribution of HLA-A, C, and DR alleles carried on HLA-B27+ haplotypes in SpA families was compared with the distribution of these alleles among HLA-B27+ haplotypes in the French general population. Contribution to SpA susceptibility of HLA-A, B, C, and DR alleles, other than HLA-B27, was tested by transmission disequilibrium test. The contribution of HLA alleles to specific presentation features of SpA was examined. RESULTS: Frequencies of HLA-A, C, and DR alleles carried on HLA-B27+ haplotypes from SpA families were comparable with those seen in the French population, except for DR13 which was overrepresented among patients (pcorr<0.001). Most interestingly, the HLA-DR4 allele was transmitted in excess to patients with SpA, independently of linkage to HLA-B27 (pcorr=0.05), and in a direction opposite to that for HLA-B27+ unaffected siblings (pcorr=0.01). Finally, the distribution of HLA alleles was not related to the presentation feature of SpA. CONCLUSION: HLA predisposition to familial SpA appears not to be limited to HLA-B27, but some HLA-DR alleles also have a significant influence. In particular, HLA-DR4 contributes significantly to a genetic predisposition to SpA, which may have implications in our understanding of SpA pathogenesis.  (+info)

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. (4/141)

BACKGROUND: In a pilot study, the anti-tumour necrosis factor alpha monoclonal antibody, infliximab, induced a rapid and significant improvement in global, peripheral, and axial disease manifestations of patients with active spondyloarthropathy. OBJECTIVE: To determine whether repeated infusions of infliximab would effectively and safely maintain the observed effect. METHODS: Safety and efficacy of a maintenance regimen (5 mg/kg infliximab every 14 weeks) was evaluated using the measurements reported in the pilot study. Of the 21 patients, 19 completed the one year follow up for efficacy; two patients changed to another dosing regimen after week 12 owing to partial lack of efficacy. However, they are still being followed up for safety analysis. RESULTS: After each re-treatment a sustained significant decrease of all disease manifestations was observed. Before re-treatment, symptoms recurred in 3/19 (16%) at week 20, in 13/19 (68%) at week 34, and in 15/19 (79%) at week 48. No withdrawals due to adverse events occurred. Twelve minor infectious episodes were observed. Twelve patients (57%) developed antinuclear antibodies; in four of them (19%) anti-dsDNA antibodies were detected. However, no lupus-like symptoms occurred. CONCLUSION: In this open study of infliximab in patients with active spondyloarthropathy, the significant improvement of all disease manifestations was maintained over a one year follow up period without major adverse events. Although recurrence of symptoms was noted in a rising number of patients before each re-treatment, no loss of efficacy was observed after re-treatment.  (+info)

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. (5/141)

OBJECTIVE: To confirm in a placebo-controlled trial the safety and efficacy profile of infliximab in short-term treatment of patients with active spondylarthropathy (SpA). METHODS: Forty patients with active SpA were randomly assigned to receive an intravenous loading dose (weeks 0, 2, and 6) of 5 mg/kg infliximab or placebo. Evaluations for efficacy and safety were performed at weeks 1, 2, 6, 8, and 12. The primary end points of this study were the improvements in patient and physician global assessments of disease activity on a 100-mm visual analog scale. RESULTS: Both primary end points improved significantly in the infliximab group compared with the baseline value, with no improvement in the placebo group. As early as week 2 and sustained up to week 12, there was a highly statistically significant difference between the values for these 2 end points in the infliximab versus the placebo group. In most of the other assessments of disease activity (laboratory measures, assessments of specific peripheral and/or axial disease), significant improvements were observed in the infliximab group compared with the baseline value and compared with placebo. Minor adverse events not causing discontinuation were equally observed in both treatment groups. There was one severe drug-related adverse event, in which a patient developed disseminated tuberculosis. CONCLUSION: Tumor necrosis factor alpha blockade with infliximab in patients with active SpA was well tolerated and resulted in significant clinical and laboratory improvements in this short-term, placebo-controlled study. However, the occurrence of tuberculosis in one patient necessitates strict inclusion criteria and long-term followup.  (+info)

Histological assessment of the early enthesitis lesion in spondyloarthropathy. (6/141)

OBJECTIVES: To describe the histological changes in acute enthesopathy in early spondyloarthropathies (SpA). METHODS: Clinically evident acute enthesopathy was confirmed by magnetic resonance imaging and ultrasonography in four cases of plantar fasciitis and one case of patellar tendon enthesitis. Ultrasound guided biopsy of insertional points was carried out with a Jamshedi needle. Control tissue was obtained from two subjects undergoing spinal grafting surgery. Standard histochemistry and immunohistochemistry analysis using the avidin-biotin immunoperoxidase complex method employing markers against CD3, CD8, CD34, and CD68 was used to determine cellular infiltrates at the insertion point. RESULTS: The enthesis architecture was abnormal in the SpA group, with increased vascularity and cellular infiltration compared with normal subjects. The predominant infiltrating cell at the enthesis fibrocartilage was the macrophage, but there was a paucity of lymphocytes at the insertion point. CONCLUSION: These preliminary findings have implications for a better understanding of the pathology in early SpA.  (+info)

Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. (7/141)

OBJECTIVE: To carry out a prospective two year follow up study comparing conventional radiography, three-phase bone scintigraphy, ultrasonography (US), and three dimensional (3D) magnetic resonance imaging (MRI) with precontrast and dynamic postcontrast examination in detecting early arthritis. The aim of the follow up study was to monitor the course of erosions during treatment with disease modifying antirheumatic drugs by different modalities and to determine whether the radiographically occult changes like erosive bone lesions of the finger joints detected by MRI and US in the initial study would show up on conventional radiographs two years later. Additionally, to study the course of soft tissue lesions depicted in the initial study in comparison with the clinical findings. METHODS: The metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints (14 joints) of the clinically more severely affected hand (soft tissue swelling and joint tenderness) as determined in the initial study of 49 patients with various forms of arthritis were examined twice. The patients had initially been divided into two groups. The follow up group I included 28 subjects (392 joints) without radiographic signs of destructive arthritis (Larsen grades 0-1) of the investigated hand and wrist, and group II (control group) included 21 patients (294 joints) with radiographs showing erosions (Larsen grade 2) of the investigated hand or wrist, or both, at the initial examination. RESULTS: (1) Radiography at the two year follow up detected only two erosions (two patients) in group I and 10 (nine patients) additional erosions in group II. Initial MRI had already detected both erosions in group I and seven (seven patients) of the 10 erosions in group II. Initial US had depicted one erosion in group I and four of the 10 erosions in group II. (2) In contrast with conventional radiography, 3D MRI and US demonstrated an increase in erosions in comparison with the initial investigation. (3) The abnormal findings detected by scintigraphy were decreased at the two year follow up. (4) Both groups showed a marked clinical improvement of synovitis and tenosynovitis, as also shown by MRI and US. (5) There was a striking discrepancy between the decrease in the soft tissue lesions as demonstrated by clinical findings, MRI, and US, and the significant increase in erosive bone lesions, which were primarily evident at MRI and US. CONCLUSIONS: Despite clinical improvement and a regression of inflammatory soft tissue lesions, erosive bone lesions were increased at the two year follow up, which were more pronounced with 3D MRI and less pronounced with US. The results of our study suggest that owing to the inadequate depiction of erosions and soft tissue lesions, conventional radiography alone has limitations in the intermediate term follow up of treatment. US has a high sensitivity for depicting inflammatory soft tissue lesions, but dynamic 3D MRI is more sensitive in differentiating minute erosions.  (+info)

Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. (8/141)

OBJECTIVE: To compare ultrasonography (US) with clinical examination in the detection of entheseal abnormality of the lower limb in patients with spondyloarthropathy (SpA). METHODS: 35 patients with SpA (ankylosing spondylitis 27; psoriatic arthritis 7; reactive arthritis 1) underwent independent clinical and ultrasonographic examination of both lower limbs at five entheseal sites-superior pole and inferior pole of patella, tibial tuberosity, Achilles tendon, and plantar aponeurosis. US was performed using an ATL (Advanced Technology Laboratories, Bothell, Washington, USA) high definition imaging 3000 machine with linear 7-4 MHz and compact linear 10-5 MHz probes to detect bursitis, structure thickness, bony erosion, and enthesophyte (bony spur). An enthesitis score was formulated from these US findings giving a possible maximum total score of 36. RESULTS: On clinical examination 75/348 (22%) entheseal sites were abnormal and on US examination 195/348 (56%) sites were abnormal. In 19 entheseal sites with bursitis on US, only five were detected by clinical examination. Compared with US, clinical examination had a low sensitivity (22.6%) and moderate specificity (79.7%) for the detection of enthesitis of the lower limbs. There was no significant correlation between the US score of enthesitis and acute phase parameters such as erythrocyte sedimentation rate (ESR) or C reactive protein (CRP). The intraobserver kappa value for analysis of all sites was 0.9. CONCLUSIONS: Most entheseal abnormality in SpA is not detected at clinical examination. US is better than clinical examination in the detection of entheseal abnormality of the lower limbs in SpA. A quantitative US score of lower limb enthesitis is proposed but further studies are required to validate it in SpA.  (+info)

Spondylarthropathies is a term used to describe a group of interrelated inflammatory diseases that primarily affect the joints of the spine (vertebral column) and the sites where the ligaments and tendons attach to the bones (entheses). These conditions also often have associations with extra-articular features, such as skin, eye, and intestinal manifestations. The most common spondylarthropathies are ankylosing spondylitis, psoriatic arthritis, reactive arthritis (formerly known as Reiter's syndrome), enteropathic arthritis (associated with inflammatory bowel disease), and undifferentiated spondyloarthropathies.

The primary hallmark of these conditions is enthesitis, which is an inflammation at the sites where ligaments or tendons attach to bones. This can lead to pain, stiffness, and limited mobility in the affected areas, particularly in the spine and sacroiliac joints (the joints that connect the base of the spine to the pelvis).

Spondylarthropathies have a strong genetic association with the human leukocyte antigen B27 (HLA-B27) gene. However, not all individuals with this gene will develop spondylarthropathies, and many people without the gene can still be affected by these conditions.

Early diagnosis and appropriate treatment of spondylarthropathies are essential to help manage symptoms, prevent joint damage, and maintain mobility and quality of life. Treatment options typically include a combination of medications, physical therapy, and lifestyle modifications.

HLA-B39 is a subtype of the human leukocyte antigen (HLA) B locus, which is part of the major histocompatibility complex (MHC) class I molecules found on the surface of most nucleated cells in the body. The HLA system plays a critical role in the immune system by presenting pieces of proteins from inside the cell to T-cells, helping the immune system distinguish between "self" and "non-self."

HLA-B39 antigen is a specific protein found on the surface of some individuals' cells. It is one of many HLA-B types, which are determined by variations in the HLA-B gene. The HLA-B39 antigen is associated with certain diseases and responses to drugs, but its role in disease susceptibility or resistance is not fully understood.

It is important to note that the presence or absence of a particular HLA type does not guarantee a specific outcome, as other genetic and environmental factors also play a significant role in determining an individual's susceptibility to diseases or responses to treatments.

HLA-B27 antigen is a type of human leukocyte antigen (HLA) found on the surface of white blood cells. HLAs are proteins that help the body's immune system distinguish its own cells from foreign substances such as viruses and bacteria.

HLA-B27 is a specific type of HLA-B antigen, which is part of the major histocompatibility complex (MHC) class I molecules. The presence of HLA-B27 antigen can be inherited from parents to their offspring.

While most people with the HLA-B27 antigen do not develop any health problems, this antigen is associated with an increased risk of developing certain inflammatory diseases, particularly spondyloarthritis, a group of disorders that affect the joints and spine. Examples of these conditions include ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and enteropathic arthritis associated with inflammatory bowel disease. However, not everyone with HLA-B27 will develop these diseases, and many people without the antigen can still develop spondyloarthritis.

Ankylosing spondylitis is a type of inflammatory arthritis that primarily affects the spine, although other joints can also be involved. It causes swelling in the spinal joints (vertebrae) that can lead to stiffness and pain. Over time, some of these joints may grow together, causing new bone formation and resulting in a rigid spine. This fusion of the spine is called ankylosis.

The condition typically begins in the sacroiliac joints, where the spine connects to the pelvis. From there, it can spread up the spine and potentially involve other areas of the body such as the eyes, heart, lungs, and gastrointestinal system.

Ankylosing spondylitis has a strong genetic link, with most people carrying the HLA-B27 gene. However, not everyone with this gene will develop the condition. It primarily affects males more often than females and tends to start in early adulthood.

Treatment usually involves a combination of medication, physical therapy, and exercise to help manage pain, maintain mobility, and prevent deformity. In severe cases, surgery may be considered.

Miller Fisher Syndrome (MFS) is a rare neurological disorder that is considered a variant of Guillain-Barré syndrome. It is characterized by the triad of symptoms including ophthalmoplegia (paralysis of the eye muscles), ataxia (loss of coordination and balance), and areflexia (absence of reflexes). Some patients may also experience weakness or paralysis in the limbs, and some cases may involve bulbar symptoms such as dysphagia (difficulty swallowing) and dysarthria (slurred speech). The syndrome is caused by an immune response that damages the nerves, and it often follows a viral infection. Treatment typically includes supportive care, plasma exchange, or intravenous immunoglobulin therapy to help reduce the severity of the symptoms.

Takayasu arteritis is a rare inflammatory disease that affects the large blood vessels in the body, most commonly the aorta and its main branches. It's also known as pulseless disease or aortic arch syndrome. The condition primarily affects young to middle-aged women, although it can occur in anyone at any age.

The inflammation caused by Takayasu arteritis can lead to narrowing, thickening, and weakening of the affected blood vessels' walls, which can result in reduced blood flow to various organs and tissues. This can cause a variety of symptoms depending on the severity and location of the vessel involvement.

Common symptoms include:

* Weak or absent pulses in the arms and/or legs
* High blood pressure (hypertension)
* Dizziness, lightheadedness, or fainting spells due to reduced blood flow to the brain
* Headaches
* Visual disturbances
* Fatigue
* Weight loss
* Night sweats
* Fever

Diagnosis of Takayasu arteritis typically involves a combination of medical history, physical examination, laboratory tests, and imaging studies. Treatment usually includes corticosteroids or other immunosuppressive medications to control inflammation and maintain remission. Regular follow-up with a healthcare provider is essential to monitor disease activity and adjust treatment as necessary.

Psoriatic arthritis is a form of inflammatory arthritis that occurs in some people with psoriasis, a skin condition characterized by scaly, red, and itchy patches. The Arthritis Foundation defines psoriatic arthritis as "a chronic disease characterized by swelling, pain, and stiffness in and around the joints. It usually affects the fingers and toes but can also affect the lower back, knees, ankles, and spine."

Psoriatic arthritis can cause a variety of symptoms, including:

* Joint pain, swelling, and stiffness
* Swollen fingers or toes (dactylitis)
* Tenderness, pain, and swelling where tendons and ligaments attach to bones (enthesitis)
* Changes in nail growth, such as pitting, ridging, or separation from the nail bed
* Fatigue and weakness
* Reduced range of motion and mobility

The exact cause of psoriatic arthritis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors. Treatment typically involves a combination of medications, lifestyle changes, and physical therapy to manage symptoms and prevent joint damage.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

I'm sorry for any confusion, but "Scandinavia" is not a medical term and does not have a medical definition. Scandinavia refers to a geographical region in northern Europe, consisting of Denmark, Norway, and Sweden. At times, Finland and Iceland are also included in the definition. If you have any questions related to medicine or health, I would be happy to try to help answer them.

An association with spondylarthropathies and psoriatic arthritis was observed in several studies. Psoriatic arthritis appears ... evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies". Arthritis Rheum. 42 (1): 175-81. doi: ...
B7 is a risk factor for cervical cancer, sarcoidosis, and early-onset spondylarthropathies.[citation needed] HLA-B7 along with ...
Conversely, deltoideal acromial enthesopathy is likely a hallmark of seronegative spondylarthropathies and its detection should ...
... spondylarthropathies MeSH C05.116.900.845.800.145 - arthritis, psoriatic MeSH C05.116.900.853.625.800.637 - reactive arthritis ... spondylarthropathies MeSH C05.550.114.865.800.145 - arthritis, psoriatic MeSH C05.550.114.865.800.150 - arthritis, reactive ...
... anomalies spina bifida Split-hand deformity Sponastrime dysplasia Spondyla-Spondyli Spondylarthritis Spondylarthropathies ...
The following conditions are typically included in the group of seronegative spondylarthropathies: Some sources also include ... which are often specifically termed seronegative spondylarthropathies. They have an increased incidence of HLA-B27, as well as ...
Treatment Patterns and Trends for Spondylarthropathies. Vanessa Caceres , April 6, 2012. Methotrexate is a commonly used ... "Spondylarthropathies: Recent Insights," which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November. ...
An association with spondylarthropathies and psoriatic arthritis was observed in several studies. Psoriatic arthritis appears ... evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies". Arthritis Rheum. 42 (1): 175-81. doi: ...
HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut ...
Critères de classification des spondylarthropathies. Rev Rhum 1990;57:85-9.. OpenUrlPubMed ...
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan. 41(1):58-67. [QxMD ... Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990 Feb. 57 ... and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a ...
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan. 41(1):58-67. [QxMD ... Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990 Feb. 57 ... and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a ...
Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis ...
Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondylarthropathies in HLA B27-positive and negative blood donors. ...
Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross- ...
... and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a ...
... spondylarthropathies, fractures, or neurological signs) in a primary care setting, there was a large decrease in pain until the ...
... sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: ...
Spondylarthropathies 25 May 2020 Mylan Nivestim filgrastim Cancer. Haematopoietic stem cell transplantation. Neutropenia 7 Jun ...
17] investigated the association between ACE I/D polymorphisms and inflammatory back pain (spondylarthropathies) secondary to ... Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondylarthropathies. J Biomed Sci ... AS, psoriatic arthritis, inflammatory bowel disease and undifferentiated spondylarthropathies in Kuwaiti Arabs. In their ...
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. ...
... and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res 2011;63 Suppl 11:S47-58. ...
Spondylarthropathies [C05.116.900.853.625.800]. *Spondylitis, Ankylosing [C05.116.900.853.625.800.850]. *Joint Diseases [ ...
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 ... Although spondylarthropathies are generally encountered in young patients, all of the spondyloarthritis subgroups are ... Toussirot E, Wendling D. Late-onset ankylosing spondylitis and related spondylarthropathies. Drugs Aging. 2005;22(6):451-69. ...
PURPOSE OF REVIEW: To assess the utility of recent genetic findings in ankylosing spondylitis (AS) and axial spondyloarthropathy (SpA) in relation to diagnostic testing, prognosis and responses to biologic treatment and the development of new therapies. RECENT FINDINGS: AS and other forms of SpA are polygenic with more than 100 genes contributing to disease susceptibility. The role of genes in determining the outcome of the disease and response to treatment is less clear. Here, we review some of the progress that has been made over the past decade in understanding the genetic contribution to these diseases and how this may be used to inform the development of new treatments. In those with a high pretest probability of SpA human leukocyte antigen (HLA)-B27 testing can increase the posttest predictive value to almost 100% in some cases. There are currently no reliable genetic predictors of disease severity or response to treatment. SUMMARY: The utility of HLA-B27 as a diagnostic tool when coupled with
Spondylarthropathies Squamous Cell Carcinoma of Head and Neck Stills disease Stomach Neoplasms ...
Spondylarthropathies. *Arthritis types: gonarthrosis, omarthrosis, spondylarthrosis, iliosacral arthritis, Heberdens nodes, ...
Spondylarthropathies Squamous Cell Carcinoma of Head and Neck Stills disease Stomach Neoplasms ...
Spondylarthropathies Squamous Cell Carcinoma of Head and Neck Stills disease Stomach Neoplasms ...
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2023 Elsevier B.V We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. Log in to Pure. ...
At SPARRC, we have thus far treated large number of cases that came to us seeking a second medical opinion about surgery to treat a variety of conditions like knee joint pain, spinal disc bulge, spinal prolapse, shoulder dislocation, ACL ligament tear etc. In over 95% of such cases, we have been able to restore the patient to optimal, pain-free state with no surgical intervention.. We have also treated elite athletes performing at national and international level competitions including basketball players , shuttle players, tennis player and football players. With SPARRC Avoid surgery Program, all these athletes have been able to return to their competitions. In SPARRC Avoid Surgery Program, the patients are given clarity about their conditions and how we differ with the diagnosis made on an MRI image. In our experience, an MRI image interpretation - a two dimensional picture on a three man dimensional reality -gives a false positive in almost 40% of the cases. This creates fear of an issue which ...
Amor B, Dougados M, Mijiyawa M: [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990, 57 (2 ...
  • An association with spondylarthropathies and psoriatic arthritis was observed in several studies. (wikipedia.org)
  • Other spondylarthropathies include psoriatic arthritis, reactive arthritis and spondylitis. (osifv.com)
  • As skeletal manifestations in SAPHO syndrome often affect the spine and have common features with ankylosing spondylitis and psoriatic arthritis (PsA), it has been considered to belong to the spondylarthropathies [ 3 ]. (biomedcentral.com)
  • 1998) Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: Evidence for antigenic selection of T cells in the synovium. (scirp.org)
  • This type of arthritis is treated in a similar fashion as other spondylarthropathies for joint symptoms. (osifv.com)
  • Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondylarthropathies in HLA B27-positive and negative blood donors. (springer.com)
  • We aimed to assess the prevalence of CVD and cardiovascular risk profile in inflammatory bowel disease (IBD), psoriasis (PSO) and spondylarthropathies (SpA). (ecco-ibd.eu)
  • It is considered to be an inflammatory joint disorder and is classified as part of the seronegative spondylarthropathies. (diseasesdic.com)
  • High levels of IL-12 have also been reported for autoimmune diseases and chronic inflammatory reactions, such as in synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies, in Sjogren's syndrome patients and atherosclerosis. (multisciences.net)
  • Inflammatory back pain or spondylarthropathies include ankylosing spondylitis (AS), psoriatic arthritis (PSA), reactive arthritis enteropathic and undifferentiated arthropathies. (nih.gov)
  • The aim of this study was to investigate an association between ACE gene I/D polymorphism and inflammatory back pain (spondylarthropathies) secondary to ankylosing spondylitis (AS), psoriatic arthritis, inflammatory bowel disease and undifferentiated spondylarthropathies. (nih.gov)
  • The NIAMS clinical research program, in partnership with other NIH intramural research programs, currently focuses its research in the areas of autoinflammatory diseases, Systemic Lupus Erythematosus, spondylarthropathies, outcomes research, vasculitis, myositis, and selected bone and dermatological diseases. (nih.gov)
  • 4) RHEUMATOLOGIC DISEASES -- Aspirin is indicated for relief of the signs and symptoms of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondylarthropathies, and arthritis and pleurisy associated with systemic lupus erythematosus. (pharmacycode.com)
  • An association with spondylarthropathies and psoriatic arthritis was observed in several studies. (wikipedia.org)